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The recent exponential increase in the use of engineered nanoparticles (eNPs) means
both greater intentional and unintentional exposure of eNPs to microbes. Intentional use
includes the use of eNPs as biocides. Unintentional exposure results from the fact that
eNPs are included in a variety of commercial products (paints, sunscreens, cosmetics).
Many of these eNPs are composed of heavy metals or metal oxides such as silver,
gold, zinc, titanium dioxide, and zinc oxide. It is thought that since metallic/metallic oxide
NPs impact so many aspects of bacterial physiology that it will difficult for bacteria
to evolve resistance to them. This study utilized laboratory experimental evolution to
evolve silver nanoparticle (AgNP) resistance in the bacterium Escherichia coli (K-12
MG1655), a bacterium that does not harbor any known silver resistance elements.
After 225 generations of exposure to the AgNP environment, the treatment populations
demonstrated greater fitness vs. control strains as measured by optical density (OD)
and colony forming units (CFU) in the presence of varying concentrations of 10 nm
citrate-coated silver nanoparticles (AgNP) or silver nitrate (AgNO3). Genomic analysis
shows that changes associated with AgNP resistance were already accumulating within
the treatment populations by generation 100, and by generation 200 three mutations had
swept to high frequency in the AgNP resistance stocks. This study indicates that despite
previous claims to the contrary bacteria can easily evolve resistance to AgNPs, and this
occurs by relatively simple genomic changes. These results indicate that care should be
taken with regards to the use of eNPs as biocides as well as with regards to unintentional
exposure of microbial communities to eNPs in waste products.
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INTRODUCTION
Experimental evolution is routinely used to study the causes and
consequences of natural selection. Specifically experimental evo-
lution can predict how phenotypes and their underlying genomic
architecture change in response to new environments. This
approach may be particular fertile for bacterial evolution. While
these organisms have persisted and diversified for billions of years,
they often must respond to novel environments. For example, the
exponential increase in products utilizing nanomaterials (NMs)
will mean increased exposure to NMs for a variety of microbes.
Increasing amounts of metallic/metallic oxide nanoparticles are
being used in consumer products. Nano-titanium oxide (nano-
TiO2) is produced on a large scale for applications in paints,
cosmetics, sunscreens, photo-catalysts and solar cells, as well
as water purification devices. The predicted concentration of
nanoTiO2 in European waters for 2009 was 20 ng/L (Gottschalk
et al., 2009). Similarly values for nano-silver were calculated at
6.6μg/kg/year, 526μg/kg/year, 0.088μg/L/year, 16.40μg/L/year,
1.29mg/kg/year, and 153μg/kg/year for American soil, sludge,
surface water, Sewage Treatment Plant (STP) effluent, STP sludge,
and sediment respectively.
In addition, metallic and metallic oxide nanoparticles are
being hailed by some as a powerful new weapon against multi-
drug resistant bacteria (Rai et al., 2012). This is motivated by
recognizing that noble metals such as silver have a long history
as antimicrobial agents with use dating back at least to 1000 BCE.
In modern times, nano silver, copper, and silica have been suc-
cessfully used in a variety of settings as both antimicrobial and
anti-insecticidal compounds. Nanosilver is now being widely used
in food packaging materials and also being proposed for use
in surgical gowns and surgical gauze (Li et al., 2006; Siqueira
et al., 2014). Silver nanoparticles (AgNPs) have been shown to
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be protective agents against numerous species of bacteria, includ-
ing Escherichia coli, Enterococcus faecalis, Staphylococcus aureus,
and several others. Other metallic and metallic oxide nanoparti-
cles have also been employed against bacteria including titanium
oxide (TiO2), magnesium oxide (MgO), copper (Cu), copper
oxide (CuO), zinc oxide (ZnO), cadmium selenium (CdSe) and
cadmium telluride (CdTe), (Duncan, 2011).
The effectiveness of NPs against both bacteria and viruses are
due to their high surface-to-volume ratio and their unique chem-
ical and physical properties. Numerous studies have now shown
that the toxicity of NPs against bacteria appears dependent on
particle composition, shape, size, and concentration (for AgNPs,
concentrations of >75μg/ml usually completely inhibits growth;
Rai et al., 2012; Tajkarimi et al., 2014). While the exact mech-
anisms of silver nanoparticle toxicity to bacteria are not fully
known, there is a growing consensus concerning the candidate
actions. First, the action of silver nanoparticles occurs both by
the release of silver ion (Ag+) as well as from potential dis-
ruption or damage to the cell wall and membrane caused by
the particles themselves (Rai et al., 2009, 2012; Mijnendonckx
et al., 2013). Silver interacts with the thiol groups in respiratory
enzymes and other proteins of bacterial cells causing them to
become inactivated (Liau et al., 1997; Feng et al., 2000). It also
binds to the cell wall and cell membrane inhibiting the respi-
ration process (Klasen, 2000; Rai et al., 2009). Silver is known
to act on E. coli by inhibiting the uptake of phosphorous and
causing the release of phosphate, mannitol, succinate, proline,
and glutamine from the cells (Yamanaka et al., 2005; Rai et al.,
2012). The penetration of silver ions inside the cell is thought
to impact the ability of DNA to replicate by causing it to con-
dense. Thus once inside, Ag+ ions may be lethal as they disrupt
metabolism, cell signaling, DNA replication, transcription, trans-
lation, and cell division, either directly or through the generation
of reactive oxygen species (ROS) (Rai et al., 2012; Mijnendonckx
et al., 2013). It is the fact that metallic/metallic oxides impact
so many aspects of bacterial physiology and reproduction that
has led some researchers to suggest that it will be difficult for
bacteria to evolve resistance to them (e.g., see discussion in Rai
et al., 2012). However, despite this claim, silver-resistant bacteria
have been repeatedly found in burn wards, clinical and natural
environments, and on human teeth (Mijnendonckx et al., 2013).
Given the projections concerning deployment of metallic, partic-
ularly silver nanoparticles for bacterial control it is important to
evaluate the evolvability of resistance to them (Gupta and Silver,
1998; Graves, 2014). This experiment utilizes a relatively naïve
laboratory bacterium, E. coli K-12 MG1655, to determine both
how quickly resistance to AgNPs can evolve and also to evaluate
the nature of the genomic changes responsible for such resistance.
MATERIALS AND METHODS
BACTERIA
E. coli K-12 MG1655 (ATCC #47076) was chosen for this study
due to the paucity of known silver or antibiotic resistant loci in
this bacterium. There are no plasmids in this strain, and the circu-
lar chromosome is composed of 4,641,652 nucleotides (GenBank:
NC_000913.3; Riley et al., 2006). Table 1 lists major antimicro-
bial resistance genes found in various microorganisms, and their
presence or absence in MG1655.
Table 1 | Major antimicrobial resistance genes in Escherichia coli.
Antimicrobial
agent
Genes MG1655 References
Streptomycin aadA1 No Momtaz et al., 2012
Gentamicin aac(3)-IIV No
Sulfonamide sul1, bla SHV, bla, CMY No
Beta lactams kpc, cmy-2, shv, tem No Xia et al., 2011
ctx-m, lap-1, bla-tem No
Ampicillin ere(A) No
Erythromycin cat A1 No Momtaz et al., 2012
Chloramphenicol cm1A No
Tetracycline tet(A), tet(B) No
Trimethoprim dfr A1 No
Quinolones qnr A No
Sulfonamide sul1, sul2 No Tadesse et al., 2012
Silver silE, sil-CFBA No Gupta et al., 2001;
Silver, 2003
Silver cusS, ompA, ompB,
ompF, ybdE
Yes Li et al., 1997; Franke
et al., 2001;
Gudipathy and
McEvoy, 2014
EVOLUTION EXPERIMENT
We cultured E. coli K-12 MG1655 using Davis Minimal Broth
(DMB,Difco™Sparks,MD )withDextrose 10% (Dextrose, Fisher
Scientific, Fair Lawn, NJ) as a sole carbon source, enriched with
thiamine hydrochloride 0.1% in 10ml of total culture volume
maintained in 50ml Erlenmeyer flasks. The flasks were placed
in a shaking incubator with temperature maintained at 37◦C
for 24 h. The stock culture was propagated by daily transfers of
0.1ml of each culture into 9.9ml of DMB for 11 days of regrowth
before selection for AgNP resistance began. The controls were
founded by taking five different 0.1ml samples and adding them
to 9.9ml of DMB broth. These cultures were allowed to grow for
24 h, typically representing 6.5 generations of population growth
from ∼106 cells per ml at hour 0–108 cells per ml at 24 h. On
the following day the treatment groups were founded by taking
0.1mL samples from each of the controls and adding them to
9.9ml of standard DMB medium with the addition of 50μg/L
or 50,000 ng/L concentration of 10 nm citrate-coated spherical
AgNPs. The nanoparticles were obtained from Nanocomposix,
San Diego, CA. The AgNPs were citrate-coated due to the need
to prevent agglomeration of the particles. Citrate was chosen for
this experiment due to the inability of citrate to be metabolized
by E. coli (Scheutz and Strockbine, 2005).
Our laboratory has studied the impact of two commonly used
silver nanoparticle coating types (citrate and polyvinylpyroli-
done, PVP) on bacteria (Tajkarimi et al., 2014). Generally, we
have found that citrate-coated AgNPs were more effective against
E. coli K-12 MG1655 than PVP-coated AgNPs. The impact of cit-
rate coating is most likely due to the charge of citrate impacting
the rate of release of Ag+ ion, as opposed to the compound itself
(El Badawy et al., 2011; Xiu et al., 2012). Control populations were
designed (C1—C5) and those cultured in AgNPs were designed as
(T1—T5). Each five generations, after transfer to found the next
generation, the remainder of each replicate was frozen at −80◦C
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for future analysis. The generation counts used in this study are
based upon the number of cell doublings of E. coli required to
grow to saturation each day after dilution in the standard DMB
broth (controls grew∼6.5 generations/per day.)We know that the
treatment populations were at least 6 generations behind the con-
trols, since they were founded 24 h later. In addition, it is unclear
whether the bacteria exposed to AgNPs were able to maintain the
same number of cell doublings as the controls due to the pres-
ence of AgNPs in their environment. This was most likely the
case early in the selection experiment, but later measurements of
the treatment populations in the presence of AgNPs suggest that
they achieved full growth each day after they acquired adaptations
allowing them to persist in the AgNP environment.
It was determined that 50μg/L (50,000 ng/L) of AgNPs
allowed some bacterial growth as indicated by observable tur-
bidity after 24 h of exposure. This concentration was chosen
as the starting point for the resistance studies. After 50 gen-
erations of culture, the culture concentration of the treatment
populations was increased to 100μg/L (100,000 ng/L). This level
was maintained for another 90 generations. After this the selec-
tion concentration was increased to125μg/L (125,000 ng/L). This
concentration was continued for another 125 generations. After
45 generations of exposure at this concentration it was observed
that several of treatment replicates were losing viability. To rescue
these populations, all replicates were combined. Five new repli-
cates were created by sampling from the mixed pool. These were
propagated without selection for AgNP resistance for an addi-
tional 40 generations before the new replicates were again exposed
to another 80 generations of 125μg/L (125,000 ng/L) AgNPs.
After 45 generations of growth in 125μg/L (125,000 ng/L)
AgNPs, these replicates were combined to form a “cocktail” to
assay their silver resistance relative to a similarly combined cock-
tail of control populations. The cocktail protocol was used due to
a shortage of labor and materials. Figure 1 shows the schedule of
exposure concentrations used in the selection protocol. After 140
generations of culture the exposure for the AgNP selected cultures
had increased by 250%.
MEASURING BACTERIAL GROWTH
Bacterial growth in BHI broth samples was assessed by measur-
ing turbidity at 620 nm for hours 0, 3, 6, 12, and 24, using a
98-well plate Synergic Mx spectrophotometer (Biotek, VA USA)
using clear polyester 98-well plates.
BACTERIAL ENUMERATION
Bacterial populations were determined by spread plating on Davis
Minimal Agar (DMA, Sigma Aldrich). In this procedure, samples
were withdrawn from inoculated samples at 0 and 24 h and were
FIGURE 1 | Evolutionary history of control and treatment populations used in this study.
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serially diluted in 0.1% peptone water. Appropriate dilutions were
plated (200μl) onto duplicate DMA plates and colonies were
counted after incubation at 37◦C overnight.
MINIMUM INHIBITORY CONCENTRATION (MIC)
MIC (Minimum Inhibitory concentration) is often defined in
different terms; however we used “lowest concentration of a
particular substance needed to inhibit the growth of a certain
population of bacteria” (Kedziora et al., 2013). In this study we
used MIC to mean the concentration that inhibited any visible
growth of the organism over 24 h. MICs were determined via
serial dilution.
GENOMIC ANALYSIS
Whole genome resequencing was utilized to identify genomic
variants associated with the greater AgNP and AgNO3 resistance
of the treatment populations compared to the controls. DNA was
extracted from each replicate population at generation 100 and
generation 200 that had been stored in the −80◦C freezer (C1—
C5; T1—T5) as well as from the ancestral E. coli K-12 MG1655
stock obtained from ATCC (designated C0) for the genomic stud-
ies. The cells used for DNA extraction were cultured for 24 h in
standard DM broth (without AgNPs). Cell density in these cul-
tures was∼108 cells/ml. Extraction of DNA followed the protocol
from Nucleic Acid Sample Preparation for Downstream Analysis:
Principles & Methods (GE Health Life Sciences, 2014). The DNA
samples were sequenced via the Illumina MiSeq sequencing plat-
form utilizing the Illumina Nextera XT kit for genomic library
preparation.
Prior to sequence alignment and variant calling, the Illumina
adapter sequences were removed from the MiSeq reads via Partek
(http://www.partek.com/). Sequence alignment and variant call-
ing from the generation 100 and 200 samples was achieved
by use of the breseq 0.24rc6 pipeline (Barrick et al., 2009;
Deatherage and Barrick, 2014). The breseq program identifies
mutations relative to a reference genome sequence. It is capable
of identifying genomic variants including single nucleotide poly-
morphisms (SNPs), insertion-deletion polymorphisms (indels),
and mutations caused by transposable insertion sequence
(IS) elements.
RESULTS
PHENOTYPES
Population growth of the control (C1—C5) and treatment (T1—
T5) populations were measured at generation 162 and 250 in the
presence of 10 nm citrate-coated AgNPs by cocktailing the con-
trol and treatment replicates. Figure 2 shows the optical density
measurement of population growth for control (red circles) and
treatment (blue squares) cocktails at generation 162 for 0μg/L
(solid line) and 250μg/L (250,000 ng/L, dashed line) citrate-
coated AgNPs. Controls showed slightly more rapid growth in
the absence of AgNPs, and at 250μg/L controls showed no
growth. At 250μg/L the treatment cocktail growth was delayed
by 12 h before growth began. The treatments were able to show
approximately a 100-fold increase through growth to saturation
during the final 12 h. Neither group showed any growth at higher
concentrations (500, 1000μg/L; 500,000 ng/L, 1,000,000 ng/L.)
FIGURE 2 | Optical density measurement of population growth is
shown for controls (red circles) and treatment (blue squares) cocktail
at generation 162 for 0µg/L (solid line) and 250µg/L (250,000ng/L,
dashed line) citrate-coated AgNPs. Controls show slightly more rapid
growth in the absence of AgNPs, at 250μg/L controls show no growth and
treatment growth is delayed by 12 h before exponential growth begins.
Neither group showed any growth at higher concentrations (500,
1000μg/L; 500,000 ng/L, 1,000,000 ng/L.).
Figures 3A,B show optical density (OD) measured growth from
generation 250 for a cocktail of control and treatment bacte-
ria at the following concentrations of AgNPs (0, 250, 500, and
750μg/L). In Figure 3A the optical density growth (0.04—0.50)
of the controls and treatment populations in 0μg/L AgNPs
corresponded to a 100-fold population increase. This was deter-
mined by counting colony-forming units (CFUs) for the cocktails
without AgNPs over that same time period. At 250μg/L both
populations show a lag in growth (exponential phases starting
at ∼6 h) and at 24 h the treatment populations are showing supe-
rior growth relative to the control cocktail that shows a decrease
in OD from hour 12 to 24. Figure 3B demonstrates that there
is no detectable growth of the control cocktail at both concen-
trations of 500 and 750μg/L (750,000 ng/L) AgNPs. Conversely,
growth is observed in the treatment cocktail, which at 500μg/L
shows an exponential phase after 6 h, but is depressed in growth
relative to the absence of AgNPs in the medium (Figure 3A).
At 750μg/L AgNPs the treatment cocktail shows an exponential
phase after 12 h and at 24 h has reached a concentration similar to
that observed in 250μg/L.
Figure 4A shows the growth of the control and treatment
cocktails in response to AgNO3 (ionic silver). Both cocktail pop-
ulations in 0μg/L AgNO3 exhibit a 2 log10 population increase.
At 250μg/L the treatment cocktail does not show an growth
phase until after 3 h, but grows to almost a 2log10 increase. At
this concentration control cocktail does not show an exponential
phase until after 6 h and only shows a 1log10 increase. Figure 4B
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FIGURE 3A | Population growth over 24h is shown for control (red
circles) and treatment (blue squares) cocktails in response to varying
concentrations of 10nm citrate-coated NPs at generation 250. The
growth of the controls and treatment populations in 0μg/L AgNPs
corresponded to 2 log10 population increase. At 250μg/L both populations
show a lag in growth (exponential phases starting at ∼6h) and at 24 h the
treatment populations are showing superior growth relative to the control
(that shows decrease from hour 12 to 24.).
FIGURE 3B | Population growth over 24h is shown for control (red
circles) and treatment (blue squares) cocktails in response to varying
concentrations of 10nm citrate-coated NPs at generation 250. There is
no detectable growth of the control cocktail at both concentrations of 500
and 750μg/L (500,000 ng/L and 750,000 ng/L ) AgNPs. At 500μg/L the
treatment cocktail does not show an exponential growth phase until after
6 h. At 750μg/L AgNPs the treatment cocktail does now show an
exponential phase until after 12 h and at 24 h has reached an optical density
of 0.360 (∼>1.5 log10 increase).
FIGURE 4A | Population growth over 24h is shown for control and
treatment cocktails in response to varying concentrations of AgNO3 at
generation 250. The growth of the controls and treatment populations in
0μg/L AgNO3 corresponded to 2 log10 population increase. At 250μg/L the
treatment cocktail does not show an exponential phase until after 3 h, but
grows to almost a 2log10 increase. At this concentration control cocktail
does not show an exponential phase until after 6 h and only shows a 1log10
increase.
FIGURE 4B | Population growth over 24h is shown for control and
treatment cocktails in response to varying concentrations of AgNO3 at
generation 250. There is no detectable growth of the control cocktail at
both concentrations of 500 and 1000μg/L. At 500μg/L the treatment
cocktail does not show an exponential phase until after 12 h, but is
depressed in growth relative to the absence of AgNO3 in the medium
(Figure 3A). At 1000μg/L (1,000,000 ng/L) AgNO3 the treatment cocktail
does now show an exponential phase until after 12 h and at 24 h is about
1log10 increase.
shows population growth for control and treatment cocktails in
response to 500 and 1000μg/L of AgNO3. There is no detectable
growth of the control cocktail at both concentrations of 500 and
1000μg/L. At 500μg/L the treatment cocktail does not show an
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exponential phase until after 12 h, but is depressed in growth rel-
ative to the absence of AgNO3 in the medium (Figure 4A). At
1000μg/L AgNO3 the treatment cocktail does not show growth
until after 12 h and at 24 h shows about a 10-fold increase in cell
density.
Figure 5A shows population growth measured by colony
forming units over 24 h for control and treatment cocktails in
response to varying concentrations of 10 nm AgNPs at genera-
tion 250. Colony forming unit (CFU) measurement is considered
a more accurate estimate of bacterial population size compared
to optical density (OD). The Figure shows that the CFU and
OD results agree. Both cocktails increased by 2.4log10 in the
absence of AgNPs. There is no detectable difference in growth
of the control and treatment cocktails at 100μg/L. However at
250, 500, and 1000μg/L the treatment cocktail shows superior
growth. At 500μg/L the treatment cocktail is still growing while
the control has shown −1.9 log10 decrease, at 1000μg/L both
have decreased with the treatment cocktail showing less reduc-
tion. Figure 5B shows population growth measured by colony
forming units over 24 h for control and treatment cocktails
in response to varying concentrations of AgNO3 at genera-
tion 250. Both cocktails increased by 2.4 log10 in the absence
of AgNPs. The data indicate that AgNO3 is more effective in
reducing bacterial growth compared to the 10 nm AgNPs. This
is illustrated by the fact that while the treatment shows posi-
tive growth exceeding the control cocktail by ∼2 log10 units at
FIGURE 5A | Population growth measured by colony forming units
over 24h is shown for control and treatment cocktails in response to
varying concentrations of 10nm AgNPs at generation 250. Both
cocktails increased by 2.4 log10 in the absence of AgNPs. There is no
detectable difference in growth of the control and treatment cocktails at
100μg/L. However at 250, 500, and 1000μg/L the treatment cocktail
shows superior growth. At 500μg/L the treatment cocktail is still growing
while the control has shown −1.9 log10 decrease, at 1000μg/L both have
decreased with the treatment cocktail showing less reduction.
100μg/; both cocktails show decrease at 250, 500, and 1000μg/L
with the treatment cocktail showing less reduction at all
concentrations.
The data from both optical density (OD) and colony form-
ing units (CFU) taken together indicate that by generation 250
of selection (∼38.5 days) the treatment populations had evolved
resistance to both citrate-coated 10 nm AgNPs and AgNO3 (ionic
silver). Resistance to 10 nm PVP-coated AgNPs, 40 nm citrate and
PVP-coated AgNPs was also illustrated by generation 250 (data
not shown).
GENOMICS
Tables 2A,B show the genomic variants there were found in the
E. coli K-12 MG1655 sample received from ATCC, relative to
the published K-12 MG1655 genome via breseq. This pipeline
uses three types of evidence to predict mutations, read align-
ments (RA), missing coverage (MC), and new junctions (JC)
(Deatherage and Barrick, 2014). Any reads that indicate a differ-
ence between the sample and the reference genome that cannot
be resolved to describe precise genetic changes are listed as “unas-
signed.” The unassigned results are not reported in this paper.
The variants can be called by either consensus or polymorphism
mode. In the former, only variants that are consistent with being
present in 100% of the reads in a sample are predicted, and in the
latter, variants present at intermediate frequencies are reported.
The data in Table 2 are reported in polymorphism mode. These
indicate that there are a few differences between the ancestral
sample of E. coli MG1655 and the reference genome that have
FIGURE 5B | Population growth measured by colony forming units
over 24h is shown for control and treatment cocktails in response to
varying concentrations of AgNO3 at generation 250. Both cocktails
increased by 2.4 log10 in the absence of AgNO3. The treatment shows
positive growth exceeding the control cocktail by ∼2 log10 units at 100μg/L.
However both cocktails show decrease at 250, 500, and 1000μg/L with the
treatment cocktail showing less reduction at all concentrations.
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been previously documented (Nahku et al., 2011). Most notable
is a 776 bp deletion that appears in the crl gene at position
257,908. This deletion was fixed (frequency= 1.00) in all reads, as
well as mutations at 2,173,361 (2 bp), 3,560,455 (i1bp, G), and
4,296,380 (i2bp, CG). The description of the genes in which each
mutation occurs are found in Table 2B.
Table 3A shows the mean and SD for selected mutation fre-
quencies for the treatment and control replicates (C1—C5 and
T1—T5) from generation 100. These replicates were created from
a common population that was grown for 11 days in standard
DMB media before being established as separate populations.
The control populations displayed a total of 28 putative polymor-
phisms, of which 5 exceeded a frequency of 0.05. The treatment
populations displayed 13 polymorphisms, of which 3 exceeded a
frequency of 0.05. The controls and treatments shared one SNP at
4,296,060 that was observed in the ancestral K-12 MG1655 strain.
This SNP was reduced in frequency and ancestral SNPs 508,302
and 2,815,694 were lost in both groups. The treatment (T4) pop-
ulation was the only population fixed (frequency = 1.000) for a
mutation in the cusS gene (593,497, T—G, D435A, GAC—GCC)
Table 2A | Ancestral K-12 MG1655 Strain (Polymorphisms) summary
of predicted mutations.
Position Mutation Freq. Gene
257,908 776 bp 1.000 [crl]
580,302 C→T 0.222 ylcI ←
2,173,361 2 bp 1.000 gatC ←
2,815,694 A→T 0.182 gshA ←
3,271,022 3 bp 0.075 garK ←
3,560,455 I + G 1.000 glpR ←/← glpR
4,296,060 C→T 0.333 gltP →/← yjcO
4,296,380 I + CG 1.000 gltP →/← yjcO
All mutations were called via breseq version 0.24rc6. In the mutation column,
D, deletion; I, insertion; arrows indicate point mutations. In the gene column,
arrows indicate the direction of the gene. If one gene name is shown the muta-
tion is within that gene. If two gene names are shown separated by a slash, then
the mutation falls within the intergenic region between those two genes.
and rpoB gene (4,182,820, C—T, H526Y, CAC—TAC). The cusS
gene is the histidine kinase in a two-component regulatory sys-
tem with cusR that senses copper ions. The rpoB gene is the
RNA polymerase beta subunit. The control (C4) population
also displayed the rpoB mutation (f = 0.247). Both the control
(C4, f = 0.223; C5 f = 1.000) and treatment (T1, f = 1.000; T2,
f = 1.000; T3, f = 0.580; T4, f = 0.000; T5, f = 1.000) popula-
tions shared another mutation in rpoB (4,182,803, C—A, P520Q,
CCG—CAG). Table 3B gives the annotation and description for
selected polymorphic SNPs in generation 100.
Table 4A shows the mean and SD for selected indel frequencies
for the treatment and control replicates (C1—C5 and T1—T5)
from generation 100. The control populations displayed a total
of 41 putative polymorphisms, of which 10 exceeded a fre-
quency of 0.05, of these 4 were ancestral and 4 shared with the
treatment populations but not ancestral. The treatment pop-
ulations displayed 45 polymorphisms, of which 10 exceeded a
frequency of 0.05, of which 4 were ancestral and 4 were shared
with the controls but not ancestral. The ancestral 3 bp dele-
tion at position 3,271,022 was lost in both groups. In addition,
the 2 bp deletion at 2,173,361 (gatC) seems to be scored by
breseq as either a 1 bp or 2 bp deletion. Two additional dele-
tions and 1 insertion appear in both groups (positions 1,299,499;
1,999 bp; 1,978,503; 776 bp; and 1,979,486; showing an inser-
tion element with an 4 bps duplicated at the target site (IS5(+)
+4bp). Table 4B gives the annotation and description for selected
polymorphic indels in generation 100.
Table 5A shows the mean and SD for selected mutation fre-
quencies for the treatment and control replicates (C1—C5 and
T1—T5) from generation 200. The control populations displayed
a total of 86 putative polymorphisms, of which 27 exceeded a
frequency of 0.05. The treatment populations displayed 16 poly-
morphisms, of which 8 exceeded a frequency of 0.05. Unlike the
data from generation 100 there are no shared SNPs that were
not present in the ancestral population (position 4,296,060 still
remains in both.) There were 4 mutations of note in the controls.
The C5 population showed a mutation in cusR, a response regula-
tor with cusS (position 594,942, E186K, GAA—AAA, f = 0.583).
C2 was fixed for a synonymous mutation in ccmE, a periplasmic
heme chaperone (position 2,295,168, V71V, GTG—GTA, f =
Table 2B | Descriptions of predicted mutations in K-12 MG1655 Ancestral Strain.
Gene Annotation Description
[crl] [crl]
ylcI ← R48R (AGG→AGA) DUF3950 family protein, DLP12 prophage
gatC ← pseudogene (1-2/442 nt) Pseudogene, galactitol-specific enzyme IIC component of PTS; transport; Transport of small
molecules: Carbohydrates, organic acids, alcohols; PTS system galactitol-specific enzyme IIC
gshA ← L249H (CTT→CAT) Glutamate-cysteine ligase
garK ← coding (747-749/1146 nt) Glycerate kinase I
glpR ←/← glpR intergenic (−2/+1) Pseudogene, DNA-binding transcriptional repressor;regulator; Energy metabolism, carbon: Anaerobic
respiration; repressor of the glp operon/pseudogene, DNA-binding transcriptional repressor; regulator;
Energy metabolism, carbon: Anaerobic respiration; repressor of the glp operon
gltP →/← yjcO intergenic (+266/+376) Glutamate/aspartate:proton symporter/Sel1 family TPR-like repeat protein
gltP →/← yjcO intergenic (+586/+56) Glutamate/aspartate:proton symporter/Sel1 family TPR-like repeat protein
All mutations were called via breseq version 0.24rc6.
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Table 3A | Control and treatment single nucleotide polymorphisms
(SNPs) summary of predicted mutations from generation 100.
Position Mutation C Mean C SD T Mean T SD Gene
593,467 T→G 0.000 0.000 0.200 0.447 cusS ←
1,311,179 T→C 0.089 0.199 0.089 0.199 tonB →
1,547,784 A→T 0.015 0.033 0.015 0.000 fdnG →
1,959,359 G→A 0.015 0.033 0.015 0.033 yecM ←
3,440,459 G→A 0.365 0.504 0.000 0.000 rpoA ←
3,815,808 A→C 0.000 0.000 0.112 0.251 pyrE ←/← rph
4,182,803 C→A 0.245 0.433 0.716 0.440 rpoB →
4,182,820 C→T 0.049 0.110 0.200 0.447 rpoB →
4,186,532 A→G 0.226 0.312 0.000 0.000 rpoC →
Mean and SD for selected mutation frequencies are shown for the treatment and
control replicates (C1—C5 and T1—T5) from generation 100. The control popu-
lations displayed a total of 28 polymorphisms, of which 5 exceeded a frequency
of 0.05. The treatment populations displayed 13 polymorphisms, of which 3
exceeded a frequency of 0.05. Blue-shaded cells, control adaptation; orange-
shaded cells, AgNP resistant adaptation; green-shaded cells are adaptations
shared by both treatments, but not observed in the ancestral MG1655.
Table 3B | Description of control and treatment single nucleotide
polymorphisms (SNPs) genes from generation 100.
Gene Annotation Description
cusS ← D435A
(GAC→GCC)
Sensory histidine kinase in
two-component regulatory system with
CusR, senses copper ions
tonB → S31P
(TCG→CCG)
Membrane spanning protein in
TonB-ExbB-ExbD transport complex
fdnG → E128D
(GAA→GAT)
Formate dehydrogenase-N, alpha subunit,
nitrate-inducible
yecM ← A163V
(GCG→GTG)
Putative metal-binding enzyme
rpoA ← R191C
(CGT→TGT)
RNA polymerase, alpha subunit
pyrE ← / ←
rph
intergenic
(−40/+26)
orotate
phosphoribosyltransferase/ribonuclease
PH (defective);enzyme; Degradation of
RNA; RNase PH
rpoB → P520Q
(CCG→CAG)
RNA polymerase, beta subunit
rpoB → H526Y
(CAC→TAC)
RNA polymerase, beta subunit
rpoC → K395E
(AAA→GAA)
RNA polymerase, beta prime subunit
Blue-shaded cells, control adaptation; orange-shaded cells, AgNP resistant adap-
tation; green-shaded cells are adaptations shared by both treatments, but not
observed in the ancestral MG1655.
1.000). There were two rpoC (RNA polymerase subunit C) muta-
tions (position 4,186,532, K395E, AAA—GAA, f = 0.916 in all
control replicates) and (position 4,186,605, H419P, CAC—CCC,
f = 0.500 in C1). Particularly notable is the rise in frequency
of mutations in cusS, purL (phosphoribylsylforml-glycineamide
synthetase), and rpoB in the treatment populations. The cusS
Table 4A | Control and treatment structural variation from generation
100.
Position Mutation C_Mean C_SD E_Mean E_SD Gene
380,013 1 bp 0.000 0.000 0.049 0.067 frmR ←/←
yaiO
770,112 3 bp 0.000 0.000 0.079 0.177 mngB →
802,819 IS1 (+)
+9 bp
0.405 0.492 0.000 0.000 ybhI →
1,299,499 1,199 bp 0.600 0.548 0.200 0.447 ychE →/→
oppA
1,978,503 776 bp 0.800 0.447 0.800 0.447 insB1–insA
1,979,486 IS5 (+)
+4 bp
1.000 0.000 0.800 0.447 insA ←/→
uspC
2,173,361 2 bp 0.800 0.447 0.400 0.548 gatC ←
2,173,362 1 bp 0.200 0.447 0.400 0.548 gatC ←
2,375,828 IS186 (+)
+4 bp
0.048 0.108 0.000 0.000 menC ←
2,379,776 3 bp 0.000 0.000 0.049 0.110 menF ←
3,815,801 1 bp 0.177 0.396 0.000 0.000 pyrE ←/←
rph
Mean and SD for selected indel frequencies are shown for the treatment and
control replicates (C1—C5 and T1—T5) from generation 100. The control popula-
tions displayed a total of 41 polymorphisms, of which 10 exceeded a frequency
of 0.05, of these 3 were ancestral and five shared with the treatment popula-
tions but not ancestral. The treatment populations displayed 45 polymorphisms,
of which 10 exceeded a frequency of 0.05, of which 3 were ancestral and
5 were shared with the controls but not ancestral. Blue-shaded cells, control
adaptation; orange-shaded cells, AgNP resistant adaptation; green-shaded cells
are adaptations shared by both treatments, but not observed in the ancestral
MG1655.
mutation at position 543,459 is at f = 0.803 in T1 and at posi-
tion 593,467 is at f = 1.000 for all five replicates. The purL
mutation (position 2,694,130) is fixed (f = 1.000) in all but T3
and the rpoB mutation (4,182,820) is fixed in all five treat-
ment replicates. These mutations are not found in the control
populations. This result is particularly interesting in that the
rpoB mutation (4,182,820) was rare in the controls in genera-
tion 100 at f = 0.049. In addition, the rpoB mutation at position
4,182,803 that was shared by both groups in generation 100
was not detected in either in generation 200. Table 5B gives the
annotation and description for selected polymorphic SNPs in
generation 200.
Table 6A shows the mean and SD for selected indel frequencies
for the control and treatment replicates (C1—C5 and T1—T5)
from generation 200. The control populations displayed a total
of 63 putative polymorphisms, of which 9 exceeded a frequency
of 0.05, of these 3 were ancestral and 5 were shared with the
treatment populations but were not ancestral. The treatment
populations displayed 34 polymorphisms, of which 12 exceeded
a frequency of 0.05, of which 3 were ancestral and 5 shared
with the control populations but not ancestral. The one indel
in the control populations was at very low frequency (position
2,552,098, 15-bp insertion in ypeA, putative acyl-CoA trans-
ferase.). However, the treatment populations had 4 indels of
significance (position 2,648,163,7bp, yfhM, a periplasmic inner
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Table 4B | Description of control and treatment indels from
generation 100.
Gene Annotation Description
frmR ←/← yaiO intergenic
(−132/+56)
Regulator protein that represses
frmRAB operon/outer
membrane protein
mngB → coding
(2135-2137/2634 nt)
Alpha-mannosidase
ybhI → coding
(933-941/1434 nt)
Putative transporter
ychE →/→ oppA intergenic
(+254/−485)
UPF0056 family inner
membrane protein/oligopeptide
transporter subunit
insB1–insA insB1, insA
insA ←/→ uspC intergenic
(−271/−264)
IS1 repressor TnpA/universal
stress protein
gatC ← pseudogene (1-2/442
nt)
Pseudogene, galactitol-specific
enzyme IIC component of PTS;
transport; Transport of small
molecules: Carbohydrates,
organic acids, alcohols; PTS
system galactitol-specific
enzyme IIC
gatC ← pseudogene (1/442
nt)
Pseudogene, galactitol-specific
enzyme IIC component of PTS;
transport; Transport of small
molecules: Carbohydrates,
organic acids, alcohols; PTS
system galactitol-specific
enzyme IIC
menC ← coding (132-135/963
nt)
O-succinylbenzoyl-CoA
synthase
menF ← coding
(866-868/1296 nt)
Isochorismate synthase 2
pyrE ←/← rph intergenic (−33/+33) Orotate phosphoribosyltrans-
ferase/ribonuclease PH
(defective);enzyme; Degradation
of RNA; RNase PH
Blue-shaded cells, control adaptation; orange-shaded cells, AgNP resistant adap-
tation; green cells are adaptations shared by both treatments, but not observed
in the ancestral MG1655.
membrane-anchored lipoprotein, T3, f = 0.498) and three dif-
ferent mutations in ompR, response regulator in two-component
regulatory system with envZ, (position 3,536,264, 1bp, T1,
f = 1.000; position 3,536,342, 12bp, T3, f = 0.947; and position
3,536,570, IS3(−) + 4bp::+TCA, T5, f = 1.000). Table 6B gives
the annotation and description for selected polymorphic indels in
generation 200.
DISCUSSION
The purpose of this study was to determine how rapidly and by
what kinds of genomic changes AgNP resistance could evolve in
a relatively naïve bacterium, E. coli K-12 MG1655. Here we have
shown this bacterium can rapidly evolve resistance to AgNPs. By
generation 162 we observed phenotypic evidence that the AgNP
resistance of the treatment populations was greater than that of
Table 5A | Control and treatment single nucleotide polymorphisms
(SNPs) from generation 200.
Position Mutation C Mean SD T Mean SD Gene
31,593* A→G 0.075 0.169 0.000 0.000 carB →
480,975 C→T 0.000 0.000 0.065 0.144 tomB ←/← acrB
533,893 C→A 0.000 0.000 0.200 0.447 allR →/→ gcl
593,459 G→A 0.000 0.000 0.161 0.359 cusS ←
593,467 T→G 0.000 0.000 1.000 0.000 cusS ←
594,942 C→T 0.117 0.261 0.000 0.000 cusR ←
2,158,055 G→C 0.053 0.118 0.000 0.000 mdtB →
2,222,961 G→A 0.069 0.153 0.000 0.000 dld →
2,295,168 C→T 0.200 0.447 0.000 0.000 ccmE ←
2,494,491 G→T 0.000 0.000 0.152 0.339 yfdX ←/→ ypdI
2,694,130 G→T 0.000 0.000 0.800 0.447 purL ←
3,416,100* T→C 0.098 0.220 0.000 0.000 acrF →
3,473,242 C→G 0.050 0.112 0.000 0.000 fusA ←
3,473,371 T→G 0.057 0.128 0.000 0.000 fusA ←
3,473,386 A→C 0.055 0.122 0.000 0.000 fusA ←
4,182,820 C→T 0.000 0.000 1.000 0.000 rpoB →
4,186,532 A→G 0.916 0.189 0.000 0.000 rpoC →
4,186,605 A→C 0.100 0.224 0.000 0.000 rpoC →
Mean and SD for selected mutation frequencies are shown for the treatment
and control replicates (C1—C5 and T1—T5) from generation 200. The control
populations displayed a total of 86 polymorphisms, of which 27 exceeded a
frequency of 0.05. The treatment populations displayed 16 polymorphisms, of
which 8 exceeded a frequency of 0.05. Blue-shaded cells, control adaptation;
red-shaded cells, AgNP resistant adaptation.
*Additional SNPs in carB, 31,599; 602; 621; 644; and 650 ranged from 0.074—
0.085 and additional SNPs in acrF were 3,416,107; 118; 121; 124; 136; 148; 151;
158; 161; and 163 ranged from 0.053—0.098.
the controls. By generation 250 we show definite resistance to
10 nm citrate-coated AgNPs as well as to ionic Ag+ (AgNO3).
Subsequent selection actually increased both AgNP and AgNO3
treatment population resistance by generation 300 to between
4.66 and 1.40 times the MIC of the controls to various sorts of
AgNP, but also to greater than 26 times the AgNO3 resistance
of the controls (Graves, 2014). The genomic analysis demon-
strates that resistance alleles were already accumulating in the
AgNP resistant populations by generation 100. The increase in
resistance we have observed does not seem to be the result of
major genomic changes. Rather, by generation 200, mutations
in four genes had swept to fixation (or nearly so) in all or
some of the treatment populations. Not surprisingly, a muta-
tion occurred in a bacterial system that is known to play a role
in regulating heavy metal concentration in the intercellular envi-
ronment (cusS; D435A (GAC→GCC) a non-synonymous point
mutation at position 593,467; this is a sensory histidine kinase
from the ompR family that is in a two-component regulatory
system with CusR, that senses copper ions). This mutation was
fixed in all five populations. Data from generation 100 suggests
that it originated in T4. A second mutation in cusS (position
593,459, R438C, CGC—TGC, f = 0.803) was also scored in T1.
(Lok et al., 2008) as well as (Gudipathy and McEvoy, 2014)
summarize the role of cusS in silver resistance. CusS is part of
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Table 5B | Description of control and treatment SNPs from generation
100.
Gene Annotation Description
carB → K259K
(AAA→AAG)
Carbamoyl-phosphate synthase large
subunit
tomB ←/←
acrB
Intergenic
(−267/+279)
Hha toxicity attenuator; conjugation-related
protein/multidrug efflux system protein
allR →/→ gcl Intergenic
(+67/−23)
Transcriptional repressor of all and gcl
operons; glyoxylate-induced/glyoxylate
carboligase
cusS ← R438C
(CGC→TGC)
sensory histidine kinase in two-component
regulatory system with CusR, senses
copper ions
cusS ← D435A
(GAC→GCC)
Sensory histidine kinase in two-component
regulatory system with CusR, senses
copper ions
cusR ← E168K
(GAA→AAA)
Response regulator in two-component
regulatory system with CusS
mdtB → V931V
(GTG→GTC)
Multidrug efflux system, subunit B
dld → K259K
(AAG→AAA)
D-lactate dehydrogenase, FAD-binding,
NADH independent
ccmE ← V71V
(GTG→GTA)
Periplasmic heme chaperone
yfdX ←/→
ypdI
intergenic
(−89/−207)
Uncharacterized protein/putative lipoprotein
involved in colanic acid biosynthesis
purL ← R472S
(CGC→AGC)
Phosphoribosylformyl-glycineamide
synthetase
acrF → Y356Y
(TAT→TAC)
Multidrug efflux system protein
fusA ← G91G
(GGG→GGC)
Protein chain elongation factor EF-G,
GTP-binding
fusA ← A48A
(GCA→GCC)
Protein chain elongation factor EF-G,
GTP-binding
fusA ← V43V
(GTT→GTG)
Protein chain elongation factor EF-G,
GTP-binding
rpoB → H526Y
(CAC→TAC)
RNA polymerase, beta subunit
rpoC → K395E
(AAA→GAA)
RNA polymerase, beta prime subunit
rpoC → H419P
(CAC→CCC)
RNA polymerase, beta prime subunit
Blue-shaded cells, control adaptation; red-shaded cells, AgNP resistant
adaptation.
the two-component sensor/responder system located next to the
CusCFBA efflux system in the E. coli genome. CusCFBA is anal-
ogous to (and shares high sequence homology with) SilCFBA
the plasmid-encoded silver resistance mechanism of Salmonella
typhimurium. CusS is a sensor that is a membrane associated gene
histidine kinase. It is autophosphorylated upon external stimuli
sensed in the periplasmic domain (in this case, Ag+ or Cu2+
stress). The cusS gene is highly conserved in other E. coli strains,
as evidenced by BLAST search using the ancestral E. coli K-12
MG1655 cusS sequence. The search returned cusS matches from
134 E. coli and Shigella strains that had 91–100% identity to the
MG1655 sequence.
Table 6A | Control and treatment structural variation from generation
200.
Position Mutation C Mean C SD T Mean T SD Gene
1,299,499 1,199 bp 0.600 0.548 0.400 0.548 ychE →/→
oppA
1,978,503 776 bp 0.600 0.548 0.800 0.447 insB1–insA
1,979,486 IS5 (+) +4bp 1.000 0.000 0.800 0.447 insA ←/→
uspC
2,173,361 2 bp 0.800 0.447 0.600 0.548 gatC ←
2,173,361 1 bp 0.187 0.419 0.400 0.548 gatC ←
2,552,098 +15 bp 0.072 0.161 0.000 0.000 ypeA ←
2,648,163 7 bp 0.000 0.000 0.100 0.223 yfhM ←
3,536,264 1 bp 0.000 0.000 0.200 0.447 ompR ←
3,536,342 12 bp 0.000 0.000 0.189 0.424 ompR ←
3,536,570 IS3 (–) +4bp::
+TCA
0.000 0.000 0.200 0.447 ompR ←
Mean and SD for selected indel frequencies are shown for the treatment and
control replicates (C1—C5 and T1—T5) from generation 200. The control popu-
lations displayed a total of 63 polymorphisms, of which 9 exceeded a frequency
of 0.05, of these 3 were ancestral and 5 were shared with the treatment
populations but were not ancestral. The treatment populations displayed 34
polymorphisms, of which 12 exceeded a frequency of 0.05, of which 3 were
ancestral and 5 shared with the control populations but not ancestral. Blue-
shaded cells, control adaptation; red-shaded cells, AgNP resistant adaptation;
green-shaded cells are adaptations shared by both treatments, but not observed
in the ancestral MG1655.
The second mutation was in purL (R472S (CGC→AGC),
a non-synonymous point mutation at position 2,694,130;
phosphoribosylformyl-glycineamide synthetase). This gene
catalyzes conversion of 5′-phosphoribosylformylglycinamide
(FGAR) to formylglycinamide in the presence of glutamine
and ATP for de novo purine nucleotide biosynthesis (Sampei
and Mizobuchi, 1989). BLAST search confirmed that the K-12
MG1655 purL consensus sequence was highly conserved across
E. coli strains, 100 matches showed from 98–100% identity.
Again, the AgNP resistant mutation was not found in any of the
E. coli or Shigella spp. sequences uncovered by the search.
The third mutation was in RNA polymerase beta subunit,
rpoB, (H526Y (CAC→TAC) a non-synonymous point mutation
at position 4,182,820; RNA polymerase, beta subunit). It was fixed
in all treatment populations, and also was first observed in C4
(f = 0.223) and T4 (f = 1.000) in generation 100. By genera-
tion 200, C4 had lost the mutation and it had become fixed in all
treatment populations. Adaptive mutations in RNA polymerase
are often found in E. coli evolution experiments (Conrad et al.,
2011), as altering its activity can have large impacts on global gene
expression patterns (Conrad et al., 2010).
The adaptive character of both of the cusS and rpoB are indi-
cated by the fact that they are non-synonymous mutations that
occur within active sites of their enzymes. The cusS mutation
is found in the histidine-kinase, DNA gyrase B, and HSP90-like
ATPase domain of the protein (Li et al., 2008; ecogene1). The
1http://www.kegg.jp/ssdb-bin/ssdb_motif?kid=eco:b0570.
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Table 6B | Description of control and treatment indels from
generation 200.
Gene Annotation Description
ychE →/→ oppA Intergenic
(+254/−485)
UPF0056 family inner membrane
protein/oligopeptide transporter
subunit
insB1–insA insB1, insA
insA ←/→ uspC Intergenic
(−271/−264)
IS1 repressor TnpA/universal
stress protein
gatC ← Pseudogene
(1-2/442 nt)
Pseudogene, galactitol-specific
enzyme IIC component of
PTS;transport; Transport of small
molecules: Carbohydrates,
organic acids, alcohols; PTS
system galactitol-specific enzyme
IIC
gatC ← pseudogene
(2/442 nt)
Pseudogene, galactitol-specific
enzyme IIC component of
PTS;transport; Transport of small
molecules: Carbohydrates,
organic acids, alcohols; PTS
system galactitol-specific enzyme
IIC
ypeA ← coding
(41/426 nt)
Putative acyl-CoA transferase
yfhM ← coding (4119-
4125/4962
nt)
Bacterial alpha2-macroglobulin
colonization factor ECAM;
anti-host protease defense factor;
periplasmic inner
membrane-anchored lipoprotein
ompR ← coding
(321/720 nt)
Response regulator in
two-component regulatory
system with EnvZ
ompR ← coding
(232-243/720
nt)
Response regulator in
two-component regulatory
system with EnvZ
ompR ← coding
(12-15/720 nt)
Response regulator in
two-component regulatory
system with EnvZ
Blue-shaded cells, control adaptation; red-shaded cells, AgNP resistant adap-
tation; green-shaded cells are adaptations shared by both treatments, but not
observed in the ancestral MG1655.
rpoB mutation occurs within the Rpb2 domain 3 site of the RNA
polymerase B (Cramer et al., 2001; ecogene2). The purL mutation
occurs prior to the enzyme’s active sites (257—389; 432—589;
and 822—966; Li et al., 1999; ecogene3). In generation 100, the
rpoB mutation was also at high frequency in C4 at f = 0.247.
This might indicate that this mutation was a general adaptation
that was useful in both the non-Ag+ and Ag+ environments.
However, by generation 200 the C4 population had lost the rpoB
mutation, while it had swept to fixation in the treatment popula-
tions. Thus it is possible that the benefit that rpoB gave was greater
for the treatments as compared to the controls. The best way to
2http://www.kegg.jp/ssdb-bin/ssdb_motif?kid=eco:b3987.
3http://www.kegg.jp/ssdb-bin/ssdb_motif?kid=eco:b2557.
determine if there is any specific Ag+ resistance derived from any
of these mutations will be to do allelic exchange experiments that
place these mutations into the ancestral bacterium and determine
if either individually or together they improve AgNP resistance.
In addition to the point mutations observed in AgNP popula-
tions in generation 200, at least three of the indels scored may
be of particular significance. Three indels (position 3,536,264,
1bp, ompR, T1, f = 1.000; position 3,536,342, 12bp, ompR,
T2, f = 0.947; position 3,536,570, IS3(-) +4bp::TCA, ompR, T5,
f = 1.000) were scored. OmpR is a DNA binding protein that is
involved in regulating gene networks (Quinn et al., 2014). While
its sequence is highly conserved in gram negative bacteria, the
collection of genes that it’s governs can vary widely. Rhee et al.
(2008) have shown that OmpR protein has only moderate speci-
ficity for its DNA sites and that this allows new specificity to
evolve via only a few mutational steps. Furthermore, OmpR has
the potential to respond to more than one environmental sig-
nal. In Salmonella Typhimurium it responds to acid stress (Quinn
et al., 2014). This bacterium is also of great interest with regards
to silver resistance, as silver resistant strains have been isolated
from both silver mines and clinical environments (McHugh et al.,
1975). Given our results we suggest that these indels in the ompR
sequence of our AgNP resistant populations may be producing
an OmpR protein that plays a new role in regulating responses to
Ag+ resistance.
SELECTIVE SWEEPS
The design of this experiment is incapable of addressing whether
the increase in AgNP resistance mutations occurred by hard or
soft sweeps. We began the experiment by sampling the ancestral
ATCC 47076 strain of K-12 MG1655 and growing up a stock cul-
ture for 11 days (∼71 generations). During this time mutations
began to accumulate in the stock culture that were not present
in the ancestral strain. The control and treatment replicates were
sampled from the stock culture and thus share genetic diversity
and recent common ancestry with each other (T1 sampled from
C1, T2 sampled from C2, etc.). For the first 100 generations of
the experiment, each of the replicate populations evolved sepa-
rately from all others. In the control replicates at generation 52/56
scored SNP/indel mutations (not ancestral) were unique to a spe-
cific replicate and most were rare. For the treatment populations,
43/46 scored SNP/indel mutations (not ancestral) were unique to
a specific population, however two of interest were already at very
high frequency (T4, position 597,467, cusS, f = 1.000 and in T1,
T2, T3, T5, position 4,183,803, rpoB, f = 1.000, 1.000, 0.580, and
1.000; T4, position 4,182,820, rpoB, f = 1.000). The rpoB muta-
tions were shared with the controls (C4, C5, position 4,183,803,
rpoB, f = 0.223, 1.000 and C3, position 4,182,820, rpoB, f =
0.247). Given that the control and treatment populations were
derived from a stock population that evolved for 71 generations,
it is possible that all of the polymorphisms were established in the
stock population before the AgNP resistance selection began.
After generation 141 the treatment populations were cock-
tailed to rescue the poor preforming replicates. This means that
cells from the T4 replicate were spread into the other populations.
By generation 200, the control populations had 138/143 putative
SNP/indel mutations that were unique to a specific population,
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and the treatment populations had 39/42 SNP/indel putative
mutations that were unique to a specific population. The later
result is somewhat startling, given the mixing of the treatments
populations in generation 141. By generation 200, the cusS and
rpoB mutations (first scored in T4) had swept to fixation in all
treatment populations, the purL mutation was fixed in 4/5 treat-
ment populations (but had not been detected in generation 100).
The most significant AgNP resistance associated indels (ompR)
were also unique to the treatment populations.
FUTURE DIRECTIONS
We are currently engaged in research to address the evolvability
of AgNp (and general Ag+ ion resistance) resistance in E. coli
K-12 MG1655. Our AgNP resistant populations were carried to
generation 305. At the time of this writing, sequencing of the gen-
eration 300 controls and treatments is underway. We have shown
that AgNP and AgNO3 resistance has increased in these popula-
tions. Our goal will be to determine if the genomic variants we
scored in generation 200, as well as new variants that may have
accumulated in the treatment replicates are involved in bring-
ing about this increased resistance. We have also selected 18 new
replicate populations for resistance to AgNO3. These populations
were all founded by single colonies derived from the ancestral K-
12 MG1655 and were never mixed. This will allow us to address
questions concerning mutational history of individual replicates
as well as to determine if evolutionary convergence occurs with
regards to AgNO3 resistance. We also wish to test whether and
which genomic variants scored in the AgNP resistance studies
reappear in the AgNO3 resistance replicates. Ultimately for defini-
tive proof of the contribution of each mutation we score to AgNP
or Ag+ resistance we will need to perform allelic exchange experi-
ments. This give us direct evidence that an individual mutation
or a set of mutations improve AgNP or Ag+ ion resistance in
the genetic background of our original E. coli K-12 MG1655
bacterium.
CONCLUSION
Experimental evolution was able to rapidly evolve resistance
to 10 nm citrate-coated AgNPs in a relatively naïve bacterium,
E. coli K-12 MG1655. Resistance required relatively few muta-
tional steps. Thus, these therapies must contend not only
with microbes receiving heavy resistance genes via horizon-
tal transfer but also with AgNP resistance readily arising
from de novo mutations in existing genes. This outcome does
not bode well for the sustained use of AgNPs as “miracle”
antimicrobials.
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